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Abstract 
Introduction: Infections with coronaviruses are not always confined to the respiratory tract and 
various neurological manifestations have been reported. The aim of this study was to perform 
a review to describe neurological manifestations in patients with COVID-19 and possible 
neuro-invasive mechanisms of Sars-CoV-2.  
Methods: Pubmed, WebOfScience and Covid-dedicated databases were searched for the 
combination of COVID-19 terminology and neurology terminology up to May 10th 2020. Social 
media channels were followed-up between March 15th and May 10th 2020 for postings with the 
same scope. Neurological manifestations were extracted from the identified manuscripts and 
combined to provide a useful summary for the neurologist in clinical practice. 
Results: Neurological manifestations potentially related to COVID-19 have been reported in 
large studies, case series and case reports and include acute cerebrovascular diseases, impaired 
consciousness, cranial nerve manifestations and auto-immune disorders such as Guillain-Barré 
Syndrome often present in patients with more severe COVID-19. Cranial nerve symptoms such 
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as olfactory and gustatory dysfunctions are highly prevalent in patients with mild-to-moderate 
COVID-19 even without associated nasal symptoms and often present in an early stage of the 
disease.  
Conclusion: Physicians should be aware of the neurological manifestations in patients with 
COVID-19, especially when rapid clinical deterioration occurs. The neurological symptoms in 
COVID-19 patients may be due to direct viral neurological injury or indirect 
neuroinflammatory and autoimmune mechanisms. No antiviral treatments against the virus or 
vaccines for its prevention are available and the long-term consequences of the infection on 
human health remain uncertain especially with regards to the neurological system. 
 
Introduction 
In December 2019, several unexplained pneumonia cases in Wuhan, China led to the detection 
of a novel coronavirus1. Infection with this virus caused symptoms resembling those caused by 
the severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East 
respiratory syndrome coronavirus (MERS‐CoV). Genomic characterization classified the virus 
as a Betacoronavirus, like MERS‐CoV and SARS‐CoV. Its entry into human host cells is 
mediated by the same receptor as in SARS‐CoV, ie. the angiotensin-converting enzyme 2 
(ACE2) receptor. Therefore, the virus was named SARS-CoV-2. The WHO named the disease 
coronavirus disease 2019 (COVID-19) and declared the outbreak of COVID-19 a pandemic on 
11 March 2020, after the disease spread to more than 100 countries and led to tens of thousands 
of cases within a few months2. The spectrum of clinical manifestations ranges from 
asymptomatic to symptoms such as fever, cough, diarrhoea and fatigue, and in some cases the 
infection eventually leads to severe pneumonia, acute respiratory distress syndrome (ARDS) 
and/or death2. Increasing evidence shows that infections with coronaviruses are not always 
confined to the respiratory tract and neurologic manifestations have been reported3. This report 
provides an overview of the currently reported neurological manifestations in patients with a 
high likelihood of an infection with SARS-CoV-2, the currently identified risk factors and the 
proposed neuro-invasive viral mechanisms (Table 1). 
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Methods 
Pubmed, WebOfScience and Covid-dedicated literature databases (MIT COVID-19 open 
research dataset, COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv) were searched 
for the combination of various COVID-19 terminology (COVID-19, coronavirus, novel 
coronavirus, SARS-CoV-2) and neurology terminology (neurological symptoms, neurological 
manifestations, neurological disorders, stroke, seizures, epilepsy, multiple sclerosis, 
neurodegenerative, movement disorder, Parkinson’s, extrapyramidal, autoimmune, 
encephalitis, encephalopathy, meningitis, headache, consciousness, neuropathy, central 
nervous system, peripheral nervous system) as well as neuroinvasive mechanisms up to May 
10th 2020. Social media channels (facebook, twitter, linked-in) were followed-up between 
March 15th and May 10th 2020 for postings with the same scope. Neurological manifestations 
were extracted from the identified manuscripts and combined when relevant to provide a useful 
summary for the neurologist in clinical practice.  
 
Neurological manifestations of SARS-CoV-2  
Neurological manifestations were reported in 36.4% of a first large series of 214 patients with 
laboratory confirmed diagnosis of SARS-CoV-2 hospitalized in three dedicated COVID-19 
hospitals in Wuhan3. Neurological symptoms were more common in patients with severe 
infection according to their respiratory status (45.5% vs 30.2% in non-severe cases) and fell 
into 3 categories: central nervous system (CNS) manifestations (dizziness, headache, impaired 
consciousness, acute cerebrovascular disease, ataxia, and seizure), cranial and peripheral 
nervous system manifestations (taste impairment, smell impairment, vision impairment, and 
neuropathy), and skeletal muscular injury manifestations. Patients with a severe respiratory 
infection were older, had more underlying disorders and showed less typical symptoms such as 
fever and cough. In line with these findings, a retrospective study from Wuhan looking at 
clinical characteristics in 113 deceased patients with COVID-19 reported disturbances of 
consciousness on admission in nearly one third of the patients4. A recent study from 2 
Strasbourg intensive care units found neurological symptoms on ICU admission in 14% (8/58) 
of patients with ARDS; 2/3 of patients demonstrated agitation when sedation and 
neuromuscular blockade were withdrawn5. In two thirds of patients, corticospinal tract signs 
were found. Of the patients already discharged at the time of reporting, 1/3 had signs of a 
dysexecutive syndrome consisting of inattention, disorientation or poorly organized movements 
in response to commands. 11/13 patients who underwent MRI due to signs of encephalopathy, 
showed bilateral frontotemporal hypoperfusion on perfusion imaging and two had a small acute 
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ischemic stroke without clinical symptoms. In 7 of these patients in whom a lumbar puncture 
was performed, RT-PCR assays of the CSF samples were negative for SARS-CoV-2. In a 
retrospective analysis of patients admitted to a neuro-COVID unit in Italy, it appeared that 
patients (56/173) had a significantly higher in-hospital mortality, delirium and disability when 
compared to neurology patients admitted in the same period without COVID-19 (117/173)6. A 
postmortem brain MRI study from Belgium in 19 patients, demonstrated brain abnormalities in 
8 non-survivors of COVID-19 such as hemorrhagic and posterior reversible encephalopathy 
syndrome related brain lesions7. 
 
1. Cerebrovascular diseases 
In the initial Wuhan retrospective series 5% of patients had new onset cerebrovascular disease 
(CVD); 5 patients were diagnosed with ischemic stroke, 1 with cerebral haemorrhage3. In all of 
these patients signs of an increased inflammatory response were found compared to patients 
without CVD such as increased CRP and extremely high levels of D-dimers. Several patients 
with CVD were older and more likely to have common cerebrovascular risk factors including 
hypertension and diabetes mellitus. The vast majority of patients had a severe respiratory 
infection. A case series from New York, reported on 4 new onset ischemic stroke patients, 
relatively early in the stage of the disease8. A report from Queens Square, London describes 6 
patients with RT-PCR confirmed COVID with new onset ischemic stroke, all due to large vessel 
occlusion and having elevated D-Dimer levels of >1000 microg/l (5/6 >7000 microg/l); 2 
patients were under anticoagulant therapy. Patients had multi-territory infarcts; two 
experienced a concurrent venous thrombosis. In 5/6 stroke occurred 8-24 days after onset of 
COVID-19 symptoms but in one patient during the pre-symptomatic phase9. 
Acute inflammation caused by infection is often followed by a procoagulant state and has been 
postulated as one of the mechanisms underlying stroke10. Studies from the Netherlands and 
France suggest that blood clots throughout the body appear in 20% to 30% of critically ill 
COVID-19 patients11,12. Coagulation dysfunctions including thrombocytopenia and D-Dimer 
increase are frequently seen in patients with COVID-19 at the beginning of the so-called 
hyperinflammatory phase (phase III) of the disease progression and are associated with negative 
clinical evolution13. The increase in D-Dimer levels appears to be higher in COVID-19 patients 
with CVD compared to patients without CVD (median levels of 900 microg/l) but this is a 
finding that will need to be further investigated and documented3,9. During the outbreak in 
2002-2003 of SARS-CoV, a study reporting on 206 patients in Singapore mentioned 5 patients 
with thromboembolic stroke and many critically ill patients who were on LMWH who still 
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developed deep venous thrombosis and pulmonary embolism suggesting the presence of a pro-
coagulant state in SARS14. From this series, vigilance for thrombotic complications including 
stroke was proposed especially in patients treated with intravenous immunoglobulins that was 
hypothesized to further increase viscosity in a hypercoagulable state. In two studies reporting 
on COVID-19 stroke patients with multiple cerebral infarcts and clinically significant 
coagulopathy, the detection of antiphospholipid antibodies has been reported9,15. 
Antiphospholipid antibodies abnormally target phospholipid proteins, and the presence of these 
antibodies is central to the diagnosis of the antiphospholipid syndrome16. These antibodies may 
arise transiently in patients with critical illness and various infections. In some patients with 
genetic predisposition, this may induce a permanent antiphospholipid syndrome, which needs 
to be investigated at least 12 weeks after the acute illness according to international guidelines17. 
2. Infections of the central nervous system 
The neuro-invasive potential of coronaviruses (CoVs) has been documented for most of the 
CoVs including SARS-CoV and MERS-CoV18-20. The presence of SARS-CoV particles as well 
as its ACE2 receptor has been demonstrated in both animal and human brains and cases of 
direct viral CNS invasion have been reported in several human CoVs20,21. SARS-CoVs have 
been detected in the CSF of a patient with encephalitis22. Due to the similarity between SARS-
CoV and SARS-CoV-2 and the presence of the ACE2 receptor in the CNS, the possibility was 
raised that SARS-CoV-2 might also lead to direct CNS infection with similar complications. 
Indeed, a recent report described the first case of meningo-encephalitis due to SARS-CoV-2, 
associated with transient generalized seizures and MRI lesions. Interestingly, SARS-CoV-2 
RNA was not detected in the nasopharyngeal swab but was detected in the CSF23.  
It is hypothesized that CNS infection with involvement and dysfunction of the cardiorespiratory 
brainstem centers may contribute to death of infected animals or patients24,25. A common 
observation in hACE2 Tg mice that were inoculated intranasally or intracranially (even at low 
doses) with SARS-CoV virus particles was a disseminated infection of the dorsal vagal complex 
(nucleus tractus solitarius, area postrema, and dorsal motor nucleus of the vagus)20. This 
complex contains afferent and efferent projections of the vagus nerve to the lungs and 
respiratory tracts indicating that the vagus nerve might be another important neuronal route for 
SARS-CoV-2 entry into the brain. In a similar way, studies on MERS-CoV have shown the 
brainstem to be heavily infected19.  
This leads to the hypothesis also made by an earlier report that death of infected animals or 
patients may be at least partially due to the dysfunction of the cardiorespiratory brainstem 
centre24,25. The cytokine storm with excessive levels of proinflammatory cytokines may also 
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contribute to the lethality of the infection18. This is illustrated by a recent report of a COVID-
19 patient with an acute necrotizing encephalopathy, a rare complication observed in infections 
with viruses including influenza, and related to a cytokine storm in the brain without direct viral 
invasion26. 
3. Seizures and epilepsy  
A Chinese multicenter retrospective study enrolled 304 patients in China, of whom 108 had a 
severe condition27. None of these patients had a known history of epilepsy. Neither acute 
symptomatic seizures or status epilepticus were observed. In 1/3 of patients, brain insults or 
metabolic imbalances known to increase the risk of seizures occurred during the disease course 
without seizure observation. From this study, there was no evidence suggesting an additional 
risk of acute symptomatic seizures in people with COVID-19. It should be noted EEGs were 
not performed in patients. In the Strasbourg ICU series, in 8 patients EEG detected nonspecific 
changes, one patient had diffuse bifrontal slowing consistent with encephalopathy5. A case 
report describes one Iranian patient who was admitted with new onset recurrent generalized 
seizures and tested positive for SARS-CoV-2 although no evidence for viral CNS invasion in 
the CSF was found and MRI was normal28.   
4. Cranial nerve disturbances 
Hypo- and anosmia have been reported to occur in the early stage of COVID-19. In the 
abovementioned observational studies in Wuhan anosmia occurred in 5.1% and dysgeusia in 
5.6% of patients3. Early reports from Europe and Israel suggested that this sudden olfactory 
dysfunction can appear in 30 to 60% of COVID-19 cases29-31. An Italian study investigating 
altered sense of smell or taste in PCR positive patients, reported that 65% of patients reported 
this symptom and of these 11% had symptoms before other symptoms; these symptoms were 
more frequent in women. 35% of patients also reported a blocked nose, 3% only had smell and 
taste symptoms32. In a recent prospective study in 417 patients with mild to moderate 
laboratory-confirmed COVID-19, conducted in 12 European hospitals, olfactory and gustatory 
dysfunctions were reported in 85.6% and 88.0% of patients respectively with a significant 
association between both disorders. Anosmia has been reported as a symptom due to infection 
with other respiratory viruses and CoVs33. While a pathogenesis related to nasal inflammation 
and related obstruction seems obvious, it has been found that symptoms occur also with high 
prevalence in patients without nasal obstruction or rhinorrhea suggesting a potentially direct 
neuro-invasion of the nervous system paths such as the olfactory bulb. The olfactory 
dysfunction appeared before (11.8%), after (65.4%) or at the same time (22.8%) as the 
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appearance of other symptoms and significantly more in women. In this study, also facial pain 
occurred in 47% of patients and dysphagia in 22%. In at least 25.5% of patients both olfactory 
and gustatory functions recovered over a 2-week period following resolution of general 
symptoms. In some patients, olfaction recovered, but not taste, and vice versa. The authors 
remark that due to the short-term observations in this study it is reasonable to think that a large 
number of these patients will recover over the weeks following resolution of the disease. Two 
COVID-19 patients with polyneuritis cranialis have been reported in Spain34; despite full 
recovery there was residual anosmia and ageusia in one case. Two American COVID-19 
patients with ophtalmoparesis and abnormal findings on MRI in cranial nerves were also 
reported35. 
5. Autoimmune and inflammatory syndromes 
Acute neuroinflammatory immune-mediated disorders caused by CoVs have been documented; 
MERS-CoV caused both ARDS and acute disseminated encephalomyelitis, and was potentially 
related to a post-infectious Guillain-Barré syndrome (GBS) with brainstem encephalitis36. 
Recently, cases of a SARS-CoV-2 infection associated with GBS have been reported as well. 
The first case report concerned a patient who had recently travelled to Wuhan and presented 
with clinical signs of a GBS on admission37. The patient developed respiratory symptoms 7 
days later and tested positive for COVID-19. A more recent study reviewing patients in three 
hospitals in northern Italy, reported on 5 patients who had GBS after the onset of COVID-1938. 
Four of the patients had a positive nasopharyngeal swab for SARS-CoV-2 at the onset of the 
neurologic syndrome and one a positive serological testing. The interval between the onset of 
symptoms of COVID-19 and the first symptoms of GBS ranged from 5-10 days. Two cases of 
Miller Fisher syndrome and polyneuritis cranialis during the COVID-2 pandemic were reported 
in Spain34; two cases with opthalmoparesis in the USA35. In all these cases PCR was positive 
for the oropharyngeal swab test but negative in the CSF. It should be noted that in the GBS and 
MFS cases, potentially auto-immune related neurological symptoms and COVID-19 primo-
infection symptoms typically occurred in close time-relationship to each other suggesting a 
para-infectious profile. Although not stated in the reports, it can be estimated that the 
neuromuscular failure associated with GBS or MFS may further compromise breathing and 
contribute to the severity of respiratory insufficiency.  
CoVs’ involvement in chronic neuroinflammatory diseases has been suggested as well. A 
significantly higher prevalence of HCoV-OC43 has been detected in brains of multiple sclerosis 
(MS) patients and CoVs have also been isolated from CSF in patients with MS39,40. 
Inflammatory molecules linked to MS could originate from infection of glial cells by CoVs41. 
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A direct link between any specific virus in neuro-inflammatory disorders, including MS, has 
not yet been described. Nevertheless, many patients with autoimmune syndromes such as MS 
might be particularly vulnerable as they are treated with disease modifying treatments (DMTs) 
that potentially increase infectious risk42. For instance, a fatal encephalitis with HCoV-OV43 
has been documented in immunocompromised patients, with infected neurons at autopsy43. 
This leads to a similar concern with SARS-CoV-2 although initial reports from series of MS 
patients that were infected with SARS-CoV-2 are gradually becoming available with a positive 
trend for patients being treated with anti-CD20 in Madrid44. 9/60 (15%) patients reported 
symptoms highly suggestive of COIVD-19, mostly without serious complications; only one 
patient was hospitalized. To tackle the specific questions around starting/stopping DMTs and 
risk/outcome for MS patients with COVID-19 the MS international federation (MSIF) and MS 
Data Alliance have set up an initiative for global data sharing45. 
6. Extrapyramidal and Neurodegenerative disorders 
Apart from the neurological symptoms described in the Strasbourg study, no reports on 
extrapyramidal symptoms have been published. We did find relevant information based on 
previous experimental work with CoVs that may be of interest to clinical neurological practice. 
In 1985, it was demonstrated that mice experimentally infected with CoVs, known to cause 
encephalitis and demyelination, demonstrate dense deposits of viral antigen in the basal 
ganglia46. In search for etiological factors for Parkinson’s disease, a decade later Fazzini et al. 
found significantly higher CSF antibodies to four coronavirus antigens in Parkinson patients 
compared to controls47. It is known from previous pre-clinical and clinical studies that drugs 
used in Parkinson’s disease, ie. the adamantanes, may have anti-viral effects and repurposing 
studies for COVID-19 may be at place48. Studies have shown interactions between SARS-CoV-
2 proteins and human proteins from various aging-related pathways49. The decreased ability to 
properly activate stress response mechanism in the elderly can lead to phenotypes that 
characterize neurodegenerative diseases such as the accumulation of aggregates. Coronavirus 
infection may, in the long-term however, lead to accelerated aging phenotypes in survivors. 
Prospective studies and registries may be useful to establish connections with aging-associated 
disorders, such as Parkinson's disease and other neurodegenerative disorders49. 
Possible neuro-invasive mechanisms of human coronaviruses  
Entry of respiratory viruses in the CNS may be mediated through a hematogenous or a neuronal 
retrograde route. In the first route, the virus will disrupt the nasal epithelium and reach the 
bloodstream and leucocytes, and - by manipulating the innate immune system - invade other 
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tissues including the CNS. Moreover, leukocytes may act as a reservoir for viral transmission 
for neuro-invasive CoVs18.  
In the second route, the virus could infect peripheral neurons and access the CNS through 
retrograde transsynaptic neuronal dissemination18. The retrograde axonal transport and 
transsynaptic transfer is well documented for other types of coronavirus such as the Swine 
Hemagglutinating Encephalomyelitis Virus (HEV) and avian bronchitis virus50,51.  
SARS-CoV and MERS-CoV have been detected mainly in neurons of brains of infected 
patients19,20. A similar neuronal tropism was also detected upon inoculation of transgenic mice 
in which expression of human ACE2 was targeted to epithelial cells using the human 
cytokeratin 18 (K18) promoter (K18-hACE2 Tg mice)20. Although the olfactory bulb is highly 
efficient at confining neuro-invasion, several viruses have been shown to enter the CNS through 
the olfactory route18. An experimental study using hACE2 Tg mice showed the olfactory nerve 
being the primary entry route of SARS-CoV to the brain. Subsequently, the virus rapidly 
spreads throughout the brain leading which likely contributes to high mortality in these mice20. 
This olfactory route for CNS invasion of SARS-CoV-2 remains to be proven, but is plausible 
as findings of anosmia associated with COVID-19 suggests the presence of the virus in the 
nasal epithelium or the olfactory bulb. Moreover, anosmia and ageusia are prevalent in COVID-
19 patients, even without other nasal symptoms33. Nevertheless, the mechanism of COVID-19 
induced anosmia remains to be elucidated as it seems that ACE2 receptors are not expressed by 
olfactory neurons and no data has been reported yet on an association of anosmia and the 
presence of CNS manifestations52,53.  
Conclusion 
Increasing evidence shows that infections with COVs are not always confined to the respiratory 
tract. Physicians should be aware of the possibility of neurological manifestations including 
acute cerebrovascular diseases, impaired consciousness, cranial nerve manifestations and auto-
immune disorders such as GBS. Olfactory and gustatory dysfunctions are both prevalent in 
patients with mild-to-moderate COVID-19 who may not have nasal symptoms. The sudden 
anosmia or ageusia need to be recognized by the international scientific community as 
important symptoms of the COVID-19. Most of the other neurological symptoms are 
demonstrated in patients with more severe COVID-19 disease and are potentially resulting from 
widespread dysregulation of homeostasis caused by major organ system damage. However, a 
part of the neurological spectrum in COVID-19 patients may be due to direct viral neurological 
injury or indirect neuroinflammatory and autoimmune mechanisms and may occur soon in the 
course of the disease. Detection of the viral nucleic acid in the CSF is rare until now; detection 
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of intrathecal synthesis of antiviral antibodies or brain autopsies on the COVID-19 patients 
could clarify the viral capacity for CNS invasion. Physicians should be aware that in patients 
with severe COVID-19, rapid clinical deterioration could be related to a neurological event 
such as encephalitis or stroke potentially contributing to its high mortality rate. Acute 
cerebrovascular disease is not uncommon in COVID-19 and the development of CVD is an 
important negative prognostic factor. There are currently no antiviral treatments against the 
virus or vaccines for its prevention. A study using affinity purification-mass spectrometry 
identified 332 high-confidence SARS-CoV-2-human protein-protein interactions. The 
identified SARS-CoV-2 viral proteins connected to a wide array of biological processes, 
including protein trafficking, translation, transcription and ubiquitination regulation. Using a 
combination of a systematic chemoinformatic drug search with a pathway centric analysis, 
close to 70 different drugs and compounds, including FDA approved drugs, compounds in 
clinical trials as well as preclinical compounds targeting parts of the resulting network, were 
listed. Currently testing of these compounds for antiviral activity therapeutic value is ongoing. 
Some of these drugs are well known to the neurological community such as valproic acid, 
haloperidol and entacapone54. The long-term consequences of the infection on human health 
remain uncertain. Aging-associated disorders such as Parkinson's disease and auto-immune 
disorders might be a potential long-term complication of SARS-CoV-2 infections. The 
European Academy of Neurology has initiated an online survey to keep track as much of 
possible of SARS-CoV-2 neurological manifestations (https://www.ean.org/ean/eancore-
covid-19) 
 
Data availability satement 
Data sharing is not applicable to this article as no new data were created or analyzed in this 
study. 
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Type of study Number & type of 
patients 
Geographical 
region 
Main 
Neurological 
manifestation  
Main findings SARS-CoV-2 RT-PCR 
throat 
swab  
naso
phary
ngeal 
swab  
CSF  
retrospective 
observational 
case series3 
n=214  
consecutive 
hospitalized 
patients 
Wuhan, China CNS, PNS, 
cranial nerve, 
muscular injury 
 neurological manifestation 
in 36%  
 impaired consciousness, 
acute cerebrovascular 
disease, ataxia, seizures, 
taste, smell and vision 
impairment, neuropathy, 
skeletal muscle injury 
 5% new onset stroke 
 neurological manifestations 
more common in patients 
with severe COVID-19 
 5% anosmia, 5% dysgeusia 
+ 
 
/ / 
retrospective 
case series4 
n=113 deceased 
vs n=161 fully 
recovered  
hospitalized 
patients 
Wuhan, China disorders of 
consciousness 
 22% conscious disorders in 
deceased vs 1% in 
recovered patients 
+ 
 
/ / 
 
observational 
case series5 
n=58 
consecutive 
admission to ICU 
due to ARDS 
Strasbourg, 
France 
neurological 
symptoms 
 neurological symptoms in 
14% on admission, in 67% 
when NM was stopped 
 agitation in 40% when NM 
was stopped 
 67% corticospinal tract 
signs 
 1/3: signs of a dysexecutive 
syndrome consisting of 
inattention, disorientation 
or poorly organized 
movements in response to 
commands 
+ / 7/7: - 
retrospective 
cohort study6 
n=173, n= 56 
COVID-19 with 
neurological 
symptoms, n=117 
neurological 
symptoms without 
COVID-19  
Brescia, 
Bologna, 
Milan, Italy 
neurological 
symptoms 
 in COVID-19 patients + 
neurological symptoms: 
significantly higher in-
hospital mortality, delirium 
and disability 
+ + / 
prospective 
case series7 
 
n=19 non-
survivors of 
COVID-19 
Belgium structural MRI 
brain 
abnormalities 
<24h of death  
 2/19: subcortical micro- 
and macrobleeds 
 1/19: PRES-related brain 
lesions 
 1/19 non-specific white 
matter lesions 
 4/19: asymmetric olfactory 
bulbs without other 
abnormalities 
+ / / 
retrospective 
case series8 
n=4 New York, 
USA 
new onset stroke  4 ischemic stroke patients 
relatively early in stage of 
disease (1/4 TIA) 
+, no further 
specification 
retrospective 
case series9 
n=6 London, UK new onset stroke  6/6: large vessel occlusion 
 6/6: multi territorial infarcts 
 6/6 elevated D-Dimer 
+, no further 
specification 
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levels of >1000 microg/l 
case report 
encephalitis22 
n=1 Japan CNS infection  meningo-encephalitis  
 generalized seizures and 
decreased consciousness 
 MRI: hyperintensity along 
the wall of R lateral 
ventricle and hyperintense 
signal changes in the R 
MTL and hippocampus 
- / + 
case report 
acute 26 
n=1 USA encephalopathy  MRI: hemorrhagic rim 
enhancing lesions within 
the bilateral thalami, MTL, 
subinsular region 
 
+ / / 
retrospective 
multicenter 
study27 
n=304 
hospitalized 
patients 
China seizures/epilepsy  no epilepsy history 
 108/304 severe COVID-19 
 0/304 acute symptomatic 
seizures or new onset 
epilepsy  
laboratory confirmed 
SARS-CoV-2, no 
further specification 
case report28 n=1 Iran seizures/epilepsy  new onset recurrent 
generalized seizures  
 MRI/CSF normal 
+ + - 
community 
survey29 
n=1702 @home 
patients using 
radar COVID-19 
app for symptom 
report 
UK hypo- and/or 
anosmia, 
dysgeusia 
 59%: loss of smell and taste RT-PCR positive, no 
further specification 
retrospective 
cohort30 
n=42, mild 
COVID-19 
hospitalized 
patients 
Tel-Aviv, 
Israel 
hypo- and 
anosmia 
 30% hypo-anosmia 
 onset 3,3 days after 
symptom onset 
 rapid recovery in most 
patients 
+ / / 
cross-sectional 
survey31 
n=59, hospitalized 
patients 
Milan, Italy hypo- and 
anosmia, 
dysgeusia 
 34%: taste or smell disorder 
 19%: taste and smell 
disorder 
 20% onset before hospital 
admission 
 more in females 
SARS-CoV-2–positive, 
no further 
specifications 
survey32 n=202 outpatients 
with mild to 
moderate 
COVID-19 
symptoms 
Treviso, 
Belluno, Italy 
hypo- and 
anosmia, 
dysgeusia 
 65%: hypo-anosmia  
 11% as a first symptom 
 more frequent in women. 
 35: % symptom of blocked 
nose 
 3%: only smell and taste 
symptoms 
+ / / 
prospective 
multicenter 
study33 
n=417 mild to 
moderate 
hospitalized 
COVID-19 
patients 
Belgium, 
France, Spain, 
Italy  
olfactory and 
gustatory 
dysfunctions 
 85.6% olfactory 
dysfunction and 
 88.0% gustatory 
dysfunction (11.8%), 
 12% before other 
symptoms 
 47% facial pain 
 22% dysphagia 
RT-PCR positive, no 
further specification 
case report34 n=2 Madrid, Spain cranial nerve 
pathology, MFS 
 CSF: albumin-cytologic 
dissociation 
 cranial nerve disturbances 
early during infection (3 
and 5 days after symptom 
/ + - 
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onset) 
case report35  n=2 USA cranial nerve 
pathology, MFS 
 ophtalmoparesis 
 early after symptom onset 
 MRI: Abnormal perineural 
or cranial nerve findings  
 
+ / - 
case report37 n=1 China GBS  symmetric leg weakness 
and areflexia 
 EMG: suggestive of 
demyelinating neuropathy 
 CSF: albumin-cytologic 
dissociation 
 early after symptom onset 
 
+ - - 
case series38 n=5 Northern Italy cranial nerve 
pathology, GBS 
 4/5 Lower limb weakness 
and paresthesias 
 1/5 facial diplegia, ataxia, 
paresthesia 
 Symptom interval: 5-10 
days 
 2/5: normal CSF protein 
n=4: 
+ 
n=1: 
serol
ogic
+ 
/ - 
 
Table 1: overview of studies, case series and case reports describing neurological 
manifestations of COVID-19 up to May 10th 2020 
 
Legend: RT-PCR: real-time reverse transcription polymerase chain reaction assay, CSF: 
cerebrospinal fluid, +: positive, -: negative, CNS: central nervous system, PNS: peripheral 
nervous system, vs: versus, ICU: intensive care unit, ARDS: acute respiratory distress 
syndrome, NM: neuromuscular blockade, LP: lumbar puncture, MRI: magnetic resonance 
imaging, PRES: posterior reversible encephalopathy syndrome, R: right-sided, MTL: medial 
temporal lobe, MFS: Miller-Fisher Syndrome, GBS: Guillain-Barré Syndrome 
